<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK97965" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK97965/" /><meta name="ncbi_pagename" content="AIP-Related Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>AIP-Related Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="AIP-Related Familial Isolated Pituitary Adenomas" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2012/06/21" /><meta name="citation_author" content="Márta Korbonits" /><meta name="citation_author" content="Ajith V Kumar" /><meta name="citation_pmid" content="22720333" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK97965/" /><meta name="citation_keywords" content="AH receptor-interacting protein" /><meta name="citation_keywords" content="AIP" /><meta name="citation_keywords" content="AIP-Related Familial Isolated Pituitary Adenomas" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="AIP-Related Familial Isolated Pituitary Adenomas" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Márta Korbonits" /><meta name="DC.Contributor" content="Ajith V Kumar" /><meta name="DC.Date" content="2012/06/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK97965/" /><meta name="description" content="AIP-related isolated familial pituitary adenoma (AIP-related FIPA) is defined as the presence of an AIP germline pathogenic variant in an individual with a pituitary adenoma (regardless of family history)." /><meta name="og:title" content="AIP-Related Familial Isolated Pituitary Adenomas" /><meta name="og:type" content="book" /><meta name="og:description" content="AIP-related isolated familial pituitary adenoma (AIP-related FIPA) is defined as the presence of an AIP germline pathogenic variant in an individual with a pituitary adenoma (regardless of family history)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK97965/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ipa/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK97965/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CDEE6E04027E100000000080D02DB.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK97965_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK97965_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/adnp-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alk-nbs/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK97965_"><span class="title" itemprop="name"><i>AIP</i>-Related Familial Isolated Pituitary Adenomas</span></h1><p class="contrib-group"><span itemprop="author">M&#x000e1;rta Korbonits</span>, MD, PhD and <span itemprop="author">Ajith V Kumar</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK97965_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK97965_ai__"><div class="contrib half_rhythm"><span itemprop="author">M&#x000e1;rta Korbonits</span>, MD, PhD<div class="affiliation small">Department of Endocrinology<br />Barts and the London School of Medicine<br />Queen Mary University of London<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lumq@stinobrok.m" class="oemail">ku.ca.lumq@stinobrok.m</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ajith V Kumar</span>, MD<div class="affiliation small">Clinical Genetics Unit<br />North East Thames Regional Genetics Service<br />Great Ormond Street Hospital<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.shn.hsog@ramuk.htija" class="oemail">ku.shn.hsog@ramuk.htija</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 21, 2012</span>.</p><p><em>Estimated reading time: 31 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ipa.Summary" itemprop="description"><h2 id="_ipa_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>AIP</i>-related <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pituitary adenoma (<i>AIP</i>-related FIPA) is defined as the presence of an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an individual with a pituitary adenoma (regardless of family history).</p><p>The most commonly occurring pituitary adenomas in this disorder are growth hormone-secreting adenomas (somatotropinoma), followed by prolactin-secreting adenomas (prolactinoma), growth hormone and prolactin co-secreting adenomas (somatomammotropinoma), and non-functioning pituitary adenomas (NFPA). Rarely TSH- or ACTH-secreting adenomas (thyrotropinoma and corticotropinoma) are observed. Clinical findings result from excess hormone secretion, lack of hormone secretion, and/or mass effects (e.g., headaches, visual field loss). Within the same family, pituitary adenomas can be of the same or different type. Age of onset in <i>AIP</i>-related FIPA is around 20-24 years (age range: 6-66 years).</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>AIP</i>-related FIPA relies on identification of characteristic pituitary adenomas based on hormone secretion, pituitary MRI, and histologic findings, and identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member<i>.</i></p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Pituitary adenomas identified in those with <i>AIP</i>-related FIPA are treated in the same manner as pituitary adenomas of unknown cause: they can be treated by surgery, medical therapy (somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists), and/or radiotherapy. Although surgery is usually performed in persons with <i>AIP</i>-related FIPA, it often does not fully control the tumor; thus, medical therapy and radiotherapy following surgery may be required to control hormone output and tumor growth.</p><p><i>Surveillance:</i> Persons with <i>AIP</i>-related FIPA who have had a pituitary adenoma need to be followed for both recurrence of a treated adenoma and development of new adenomas. No specific guidelines exist; the authors' recommendations are:</p><ul><li class="half_rhythm"><div>Yearly clinical assessment and pituitary function tests (IGF-1, spot GH, prolactin, LH/FSH, estradiol/testosterone, TSH, fT4, and morning cortisol);</div></li><li class="half_rhythm"><div>Dynamic testing to evaluate for hormone excess or deficiency (e.g., glucose tolerance test, insulin tolerance test) as needed; and</div></li><li class="half_rhythm"><div>Follow-up pituitary MRI, with frequency depending on clinical status, previous extent of the tumor, and treatment modality.</div></li></ul><p>Clinical monitoring of secondary complications of the tumor and/or its treatment (e.g., diabetes mellitus, hypertension, osteoarthritis, hypogonadism, osteoporosis) are necessary.</p><p><i>Evaluation of relatives at risk:</i> Family members at risk for <i>AIP</i>-related FIPA warrant <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to identify those who harbor the variant and thus require surveillance over time for pituitary adenomas.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>AIP</i>-related FIPA is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Each child of an individual with <i>AIP</i>-related FIPA has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis for pregnancies at increased risk is possible if the <i>AIP</i> pathogenic variant of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member has been identified; however, requests for prenatal testing for conditions which (like FIPA) do not affect intellect and have some treatment available are rare. Furthermore, as <i>AIP</i>-related FIPA demonstrates reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, the finding of a <i>AIP</i> pathogenic variant prenatally does not allow accurate prediction of whether a tumor will develop, the adenoma type, age of onset, prognosis, availability of and/or outcome of treatment.</p></div></div><div id="ipa.Diagnosis"><h2 id="_ipa_Diagnosis_">Diagnosis</h2><p><i>AIP</i>-related <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pituitary adenoma (<i>AIP</i>-related FIPA) is defined as the presence of an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an individual with a pituitary adenoma (regardless of family history).</p><p>The pituitary adenomas can be:</p><ul><li class="half_rhythm"><div>Growth hormone-secreting (somatotropinoma)</div></li><li class="half_rhythm"><div>Prolactin-secreting (prolactinoma)</div></li><li class="half_rhythm"><div>Growth hormone and prolactin co-secreting (somatomammotropinoma)</div></li><li class="half_rhythm"><div>Non-functioning pituitary adenoma (NFPA)</div></li><li class="half_rhythm"><div>TSH- or ACTH-secreting (thyrotropinoma and corticotropinoma)</div><div>Note: These are rare; thyrotropinoma has been observed in one person with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Multihormonal (i.e., secreting more than one pituitary hormone)</div></li></ul><div id="ipa.Testing"><h3>Testing</h3><p>Pituitary adenomas can be categorized by cell-type origin, hormone-secreting activity, and/or size. Tumors smaller than 10 mm in diameter are considered microadenomas; tumors larger than 10 mm in diameter are considered macroadenomas. Virtually all pituitary tumors are benign adenomas; pituitary carcinomas are very rare. Despite the benign histologic nature of the pituitary adenomas, they can cause morbidity through hormone dysfunction and/or mass effects (i.e., the tumor compression syndrome).</p><p>The diagnostic changes in hormone secretion, findings on imaging, and histology of each tumor type are reviewed in <i>Endocrinology</i> [<a class="bk_pop" href="#ipa.REF.de_groot.2010">De Groot &#x00026; Jameson 2010</a>]. The following is a brief summary.</p><p><b>Somatotropinoma</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Growth hormone (GH) secretion.</b> The diagnostic test for somatotropinoma is an oral glucose tolerance test (oGTT) using 75 mg glucose. Controls fully suppress GH secretion to undetectable levels, whereas persons with a somatotropinoma fail to suppress growth hormone below 1 mU/L; some show a paradoxic increase in growth hormone concentration [<a class="bk_pop" href="#ipa.REF.katznelson.2011.1">Katznelson et al 2011</a>].</div><div class="half_rhythm">Note: (1) IGF-1 levels are invariably high in individuals with severe untreated somatotropinoma; however, divergent GH and IGF-I values may be seen in up to 30% of patients: the most common discrepancy is an elevated IGF-I level with a normal GH value, thought to reflect earlier disease. Of note, age-related IGF-1 normal ranges need to be used to interpret test results. (2) The diagnosis of somatotropinoma can be difficult to establish in adolescents: during peak growth velocity GH levels can be high and not fully suppressed during oGTT; IGF-1 levels range widely and can vary by stage of puberty. False-positive responses to the oGTT may also be seen in patients with diabetes mellitus, liver disease, renal disease, or anorexia nervosa. (3) About half of GH-secreting pituitary adenomas with pathogenic variants in <i>AIP</i> co-secrete prolactin, which may be due to co-secretion and/or the "stalk effect" (i.e., high hormone levels that result from compression of the pituitary stalk and decreased inhibitory dopaminergic input). (4) Deficiency of other pituitary hormones is often seen in macroadenomas.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Imaging.</b> Contrast-enhanced pituitary MRI is the imaging modality of choice. By the time they cause symptoms and biochemical abnormalities, the overwhelming majority of somatotropinomas are macroadenomas and are sufficiently large to be detected by MRI; however, tumors may not be detectable in their early stages. Note: With modern imaging techniques and contrast agents, tumors as small as 2 mm can be identified.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Histology.</b> Immunostaining for growth hormone is usually positive in somatotropinomas. Immunostaining for prolactin is often positive with or without clinical or biochemical hyperprolactinemia. In somatomammotropinomas both GH and PRL staining are positive.</div><div class="half_rhythm">Somatotropinomas can be classified into sparsely and densely granulated adenomas using electron microscopy or a cytokeratin stain (e.g., Cam5.2 or CK8). Persons with <i>AIP</i>-related FIPA often have sparsely granulated adenomas.</div><div class="half_rhythm">Somatotroph (growth hormone-secreting) cell hyperplasia has been described in a few cases of <i>AIP</i>-related FIPA and acromegaly. Note: Somatotroph cell hyperplasia can be distinguished from somatotropinoma by reticulin staining.</div></li></ul><p><b>Prolactinoma</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Prolactin (PRL)</b>
<b>secretion.</b> PRL concentration can be assessed from a random serum sample.</div><div class="half_rhythm">Note: (1) Due to common interference of assays for prolactin with macroprolactin, it is important for the laboratory to perform PEG (polyethylene glycol) precipitation at the initial assessment. (2) Macroprolactinomas can be associated with paradoxically normal or only slightly elevated levels of prolactin as a result of the hook effect (i.e., falsely low values on the prolactin immunoassay in the presence of an overwhelming amount of antigen [prolactin] that affects the binding capacity of the added antibody). (3) Some of the numerous causes of hyperprolactinemia without pituitary adenoma are pregnancy, lactation, exercise, stress, certain drugs, and polycystic ovary syndrome. Pituitary lesions that do not produce prolactin can also cause high prolactin levels due to the stalk effect. (4) About half of the <i>AIP</i>-mutation positive GH-secreting pituitary adenomas co-secrete prolactin.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Imaging.</b> Contrast-enhanced pituitary MRI is the imaging modality of choice. Sometimes pituitary microadenomas too small to be detected on MRI can cause elevated serum concentrations of prolactin. With modern imaging techniques and contrast agent, tumors as small as 2 mm can be identified.</div><div class="half_rhythm">The overwhelming majority of prolactinomas in persons with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are macroadenomas.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Histology.</b> Immunostaining for prolactin is usually positive. In somatomammotropinomas both GH and PRL staining are positive.</div></li></ul><p><b>Non-functioning pituitary adenoma (NFPA)</b></p><ul><li class="half_rhythm"><div><b>Hormone secretion.</b> By definition, no clinically relevant increase in hormone secretion is observed; however, low-level increases in FSH secretion can be observed.</div></li><li class="half_rhythm"><div><b>Imaging.</b> Contrast-enhanced pituitary MRI detects clinically relevant NFPAs.</div></li><li class="half_rhythm"><div><b>Histology.</b> More than 95% of NFPAs are of gonadotroph origin; immunostaining for LH/FSH can be observed in scattered cells.</div><ul><li class="half_rhythm"><div>"Null" adenomas are those in which no immunostaining for any pituitary hormones is evident.</div></li><li class="half_rhythm"><div>"Silent" ACTH, GH, or GH and PRL adenomas (i.e., non-functioning adenomas in which immunostaining is positive for ACTH, GH, or PRL) have been described in persons with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></li></ul><p><b>Thyrotropinoma</b></p><ul><li class="half_rhythm"><div><b>TSH secretion.</b> Serum concentrations of TSH are normal or high in the presence of elevated total and/or free thyroid hormone concentrations. Note: Measurement of markers of peripheral thyroid hormone action and dynamic tests of thyroid function may distinguish a thyrotropinoma from the syndrome of resistance to thyroid hormone.</div></li><li class="half_rhythm"><div><b>Imaging.</b> Contrast-enhanced pituitary MRI is the imaging modality of choice. Thyrotropinomas are often, but not always, macroadenomas.</div></li></ul><p><b>Corticotropinoma</b></p><ul><li class="half_rhythm"><div><b>ACTH secretion.</b> The diagnosis of Cushing disease can be difficult and may require dynamic testing, abnormal circadian rhythm, and sometimes petrosal sampling.</div></li><li class="half_rhythm"><div><b>Imaging.</b> Contrast-enhanced pituitary MRI is the imaging modality of choice.</div></li><li class="half_rhythm"><div><b>Histology.</b> Immunostaining for ACTH is observed in most cases; Crook's change (hyalinization) can be observed in some.</div></li></ul><div id="ipa.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Gene.</b> By definition <i>AIP</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants cause <i>AIP</i>-related <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenomas.</p><div id="ipa.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>AIP</i>-Related Familial Isolated Pituitary Adenomas</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97965/table/ipa.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ipa.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>AIP</i></td><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>5</sup></td><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>7,&#x000a0;8</sup></td><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions</td><td headers="hd_h_ipa.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ipa.TF.1.1"><p class="no_margin">See <a href="/books/NBK97965/#ipa.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ipa.TF.1.2"><p class="no_margin">See <a href="#ipa.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="ipa.TF.1.3"><p class="no_margin">The ability of the test method used to detect a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="ipa.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="ipa.TF.1.5"><p class="no_margin">One promoter variant has been reported. See <a href="/books/NBK97965/bin/ipa-Table4.pdf">Table 4</a> (pdf).</p></div></dd><dt>6. </dt><dd><div id="ipa.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#ipa.REF.georgitsi.2008b.4146">Georgitsi et al [2008b]</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al [2010]</a></p></div></dd><dt>7. </dt><dd><div id="ipa.TF.1.7"><p class="no_margin">Testing that identifies deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA; included in the variety of methods that may be used are <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>8. </dt><dd><div id="ipa.TF.1.8"><p class="no_margin">If laboratories are using commercial MLPA kits, the probes for <i>AIP</i> are typically combined with the probes for <i>MEN1</i> (see <a href="/books/n/gene/men1/">Multiple Endocrine Neoplasia Type 1</a>); such kits can detect deletions or duplications in both genes.</p></div></dd></dl></div></div></div></div></div><div id="ipa.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis of <i>AIP</i>-related FIPA</b>
<b>in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with a pituitary adenoma in whom <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be considered are those who do not have a clinical diagnosis or features of a recognized syndrome or a pathogenic variant in one of the genes known to cause <a href="/books/n/gene/men1/">multiple endocrine neoplasia type 1</a> or type 4 (<i>MEN1</i> or <i>MEN4</i>) or <a href="/books/n/gene/carney/">Carney complex</a>, and who have <b>one or more</b> of the following [<a class="bk_pop" href="#ipa.REF.korbonits.2012.351">Korbonits et al 2012</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">A family history of more than one individual with a pituitary tumor [<a class="bk_pop" href="#ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</a>]</div><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in approximately 20% of families with FIPA [<a class="bk_pop" href="#ipa.REF.chahal.2010.419">Chahal et al 2010</a>] and in 40% of families in which somatotroph adenomas are the only tumor type observed.</div><div class="half_rhythm">Note: To date, <i>AIP</i> pathogenic variants have not been identified in families with two adults with microprolactinomas; therefore, the probability of identifying an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in such a family is low.</div></li><li class="half_rhythm"><div class="half_rhythm">Pituitary adenoma diagnosed before age 18 years</div><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in approximately 20% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of childhood-onset somatotroph adenoma [<a class="bk_pop" href="#ipa.REF.chahal.2010.419">Chahal et al 2010</a>, <a class="bk_pop" href="#ipa.REF.cazabat.2011.1973">Cazabat et al 2011</a>, <a class="bk_pop" href="#ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</a>].</div><div class="half_rhythm">Note: The apparent absence of a family history in such individuals could result from reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or lack of information about the family. A <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been described in one individual [<a class="bk_pop" href="#ipa.REF.stratakis.2010.457">Stratakis et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">No apparent family history of pituitary adenomas and <b>one</b> of the following:</div><ul><li class="half_rhythm"><div class="half_rhythm">A pituitary macroadenoma diagnosed before age 30 years [<a class="bk_pop" href="#ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</a>], especially a growth hormone-secreting pituitary tumor [<a class="bk_pop" href="#ipa.REF.cazabat.2007.1">Cazabat et al 2007</a>, <a class="bk_pop" href="#ipa.REF.georgitsi.2008a.621">Georgitsi et al 2008a</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">A prolactin-secreting macroadenoma [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>, <a class="bk_pop" href="#ipa.REF.cazabat.2011.1973">Cazabat et al 2011</a>]</div><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in 11% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., no apparent family history of pituitary adenomas) of young-onset (age &#x0003c;30 yrs) pituitary macroadenomas [<a class="bk_pop" href="#ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</a>].</div></li></ul></li></ul><p>The <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> strategy for <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants:</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></dd><dt>2.</dt><dd><p class="no_top_margin">If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, perform <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing.</p></dd></dl><p><b>Predictive testing</b> for at-risk asymptomatic family members requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p></div></div><div id="ipa.Clinical_Characteristics"><h2 id="_ipa_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ipa.Clinical_Description"><h3>Clinical Description</h3><p>The most common pituitary adenomas observed in <i>AIP</i>-related <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenoma (<i>AIP-</i>related FIPA) are somatotropinoma (growth hormone-secreting), followed by somatomammotropinoma (growth hormone- and prolactin-secreting) and prolactinoma (prolactin-secreting) [<a class="bk_pop" href="#ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</a>, <a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al 2007</a>, <a class="bk_pop" href="#ipa.REF.leontiou.2008.2390">Leontiou et al 2008</a>]. Clinically non-functioning pituitary adenomas (NFPAs) are also identified. Rarely, TSH-secreting or ACTH-secreting adenomas have been identified.</p><p>In the <a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al [2007]</a> cohort, 36% had a GH adenoma, 42% had a PRL adenoma, 14% had NFPA, and 8% had an ACTH-, TSH- or FSH-oma. In the <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al [2010]</a> study, 68% had a GH or mixed GH/PRL adenoma, 20% had PRL adenoma, 11% had NFPA, and 1% had ACTH-, TSH-, or FSH-oma. Of note, within the same family different relatives with the same <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can have different types of adenomas.</p><p>The following is true of <i>AIP-</i>related FIPA as well as all types of pituitary adenomas. Histologically, pituitary adenomas are benign; however, because of their hormonal activity, location, size, and proximity to important structures, the prognosis depends on the stage of the tumor at diagnosis; the morbidity of tumors diagnosed at an advanced stage (i.e., with invasion of surrounding structures) tends to be high.</p><p>The median age of diagnosis of <i>AIP-</i>related FIPA is 23 years. The earliest age of diagnosis of a pituitary tumor in a person with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is six years; the oldest is 78 years [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>, <a class="bk_pop" href="#ipa.REF.chahal.2011.43">Chahal et al 2011</a>].</p><ul><li class="half_rhythm"><div>In 20 families with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, 16 had at least one member with pituitary gigantism (i.e., childhood-onset somatotropinoma) and/or disease onset before age 18 years, while only three of the 44 families with FIPA who did not have an <i>AIP</i> pathogenic variant had a member with pituitary gigantism and/or disease onset before age 18 years [<a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>].</div></li><li class="half_rhythm"><div>Of 75 persons who had an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, over 52% had childhood- or adolescent-onset somatotropinoma; 4% of persons who were <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases without an <i>AIP</i> pathogenic variant had a somatotropinoma [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</div></li></ul><div id="ipa.Hormone_Dysfunction"><h4>Hormone Dysfunction</h4><p><b>Somatotropinoma</b> (growth hormone-secreting pituitary adenoma)</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Acromegaly.</b> Approximately 80%-85% of persons with <i>AIP</i>-related FIPA have acromegaly. Persons with acromegaly have excess growth hormone secretion resulting in enlargement of the hands and feet, and coarse facial appearance with prognathism and malocclusion of the teeth. They may have headaches, joint pain, carpal tunnel syndrome, sleeping difficulties, excessive sweating, hypertension, diabetes mellitus, and muscle weakness. Individuals with acromegaly of any cause are at increased risk for colon cancer.</div><div class="half_rhythm">If acromegaly starts in childhood/adolescence it can lead to pituitary gigantism (see following).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Pituitary gigantism.</b> Excessive growth hormone secretion before the fusion of the growth plates results in pituitary gigantism. Exceptionally tall stature results from a combination of high GH levels and delayed onset of puberty due to suppression of LH/FSH secretion by mass effect of the tumor and/or, when present, the direct effect of high prolactin levels.</div><div class="half_rhythm">One third of all individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and 40%-50% of persons with an <i>AIP</i> mutation-positive GH-secreting adenoma have pituitary gigantism [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</div></li></ul><p><b>Prolactinomas.</b> Approximately 10%-15% of persons with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a prolactinoma [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>]. Prolactinomas result in signs and symptoms of prolactin excess (i.e., amenorrhea, sexual problems, galactorrhea, and infertility) and can also cause mass effects (e.g., visual field defects, headaches).</p><p>Almost all <i>AIP</i>-related prolactinomas are macroadenomas with male predominance [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>]. In contrast, prolactinomas in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families without an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be both macro- and microadenomas.</p><p><b>Non-functioning pituitary adenomas (NFPAs).</b> NFPAs are seen in 4%-7% of persons with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>NFPAs are usually diagnosed due to the local effects of the tumor, such as bitemporal hemianopia or hypogonadism. It is unclear why these silent adenomas do not release hormones at a clinically recognizable level; however, there is likely to be a continuum between fully functional and completely silent adenomas. Distinguishing NFPA from prolactinomas can occasionally be difficult due to the stalk effect.</p><p>In <i>AIP</i>-related FIPA, NFPAs are often (but not always) silent somatotroph or lactotroph adenomas [<a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>, <a class="bk_pop" href="#ipa.REF.villa.2011.347">Villa et al 2011</a>]. In families with <i>AIP</i>-related FIPA, NFPAs are identified at a younger age than NFPAs in persons without a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</p><p>Note: NFPAs are more common in families with FIPA without an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> than in families with <i>AIP-</i>related FIPA. NFPAs in families with FIPA who do not have an <i>AIP</i> pathogenic variant are most often silent gonadotroph adenomas.</p><p><b>TSH-secreting adenomas</b> (causing hyperthyroidism) and <b>ACTH-secreting adenomas</b> (causing Cushing disease) are rarely seen in FIPA.</p><p>A single individual with <i>AIP</i>-related FIPA and a thyrotropinoma, and a single individual with FIPA, a thyrotropinoma, and no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AIP</i> have been described [<a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al 2007</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</p><p>Two <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases with <i>AIP</i>-related FIPA with Cushing disease have been described. Of 74 children with Cushing disease, the one child found to harbor an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had an aggressive tumor [<a class="bk_pop" href="#ipa.REF.stratakis.2010.457">Stratakis et al 2010</a>]. Another individual with Cushing disease was described by <a class="bk_pop" href="#ipa.REF.georgitsi.2007a.4101">Georgitsi et al [2007a]</a>.</p><p>Note: A few families with homogeneous pituitary adenoma phenotypes (i.e., pituitary tumors of the same type) and heterogeneous phenotypes (i.e., pituitary tumors of different types) with FIPA without an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with Cushing disease have been described [<a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al 2007</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>].</p><p><b>Other.</b> Subfertility is common in persons with pituitary tumors. No data are available specifically regarding subfertility in <i>AIP</i>-related FIPA.</p><p><b>Mass effects.</b> Large pituitary adenomas can be associated with deficiencies of other pituitary hormones that result in subfertility, hypothyroidism, hypoadrenalism, low levels of growth hormone, and panhypopituitarism.</p><p>Macroadenomas (&#x0003e;10 mm diameter) may also press on the optic chiasm and optic tracts causing bitemporal hemianopia. The tumor may invade the adjacent cavernous sinus. Headache can be present in any type of adenoma but is especially common in acromegaly; the mechanism for the increased frequency is unknown.</p><p>Larger pituitary tumors may autoinfarct, resulting in pituitary apoplexy (sudden-onset severe headache, visual disturbance, cranial nerve palsies, hypoglycemia, and hypotensive shock). Pituitary apoplexy has been described in individuals with <i>AIP</i>-related FIPA [<a class="bk_pop" href="#ipa.REF.chahal.2011.43">Chahal et al 2011</a>].</p><p><b>Pituitary carcinoma.</b> To date pituitary carcinoma has not been described in an individual with <i>AIP</i>-related FIPA.</p><p><b>Other, non-pituitary tumors</b> have been observed in some families with <i>AIP</i>-related FIPA; however, because the background population risk for tumors is fairly high and because no consistent pattern has been observed, at present there is no conclusive evidence that an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> increases the risk for any other tumors.</p></div></div><div id="ipa.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The question of <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation in <i>AIP</i>-related FIPA is controversial. The majority (70%) of <i>AIP</i> variants result in a truncated protein.</p><ul><li class="half_rhythm"><div>Some have suggested that individuals with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in a truncated protein manifest symptoms at a significantly younger age than those with a pathogenic variant that preserves the structure of the C-terminal end of the protein (22.7 +/- 9.6 vs. 29.8 +/- 10.9 years, respectively) [<a class="bk_pop" href="#ipa.REF.cazabat.2009.132">Cazabat et al 2009</a>]; however, data from the two largest cohorts of those with <i>AIP</i>-related FIPA do not support this finding [<a class="bk_pop" href="#ipa.REF.cain.2010.681">Cain et al 2010</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</div></li><li class="half_rhythm"><div>Penetrance was no higher in persons with a pathogenic truncating variant than in those with a non-truncating variant [<a class="bk_pop" href="#ipa.REF.cain.2010.681">Cain et al 2010</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>].</div></li></ul></div><div id="ipa.Penetrance"><h3>Penetrance</h3><p>Studies on large families with <i>AIP</i> pathogenic variants show a clinical <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of pituitary tumors of approximately 15%-30% [<a class="bk_pop" href="#ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</a>, <a class="bk_pop" href="#ipa.REF.naves.2007.383">Naves et al 2007</a>, <a class="bk_pop" href="#ipa.REF.chahal.2011.43">Chahal et al 2011</a>]. Although some families with <i>AIP-</i>related FIPA can show high penetrance, the higher levels of penetrance initially reported in some families is probably ascertainment bias due to insufficient information on all at-risk family members (e.g., lack of medical records, information on pituitary hormone testing, and/or imaging studies) [<a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al 2007</a>, <a class="bk_pop" href="#ipa.REF.leontiou.2008.2390">Leontiou et al 2008</a>].</p><p>The factors influencing <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> are not known; the possibility of a second <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> has been investigated [<a class="bk_pop" href="#ipa.REF.khoo.2009.1057">Khoo et al 2009</a>].</p></div><div id="ipa.Anticipation"><h3>Anticipation</h3><p>Genetic <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> is not observed in <i>AIP</i>-related FIPA. However, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> second- or third-generation family members may be diagnosed earlier than members of the first generation because of greater awareness of the disorder and, thus, earlier recognition of the significance of adenoma-related symptoms [<a class="bk_pop" href="#ipa.REF.daly.2006.4769">Daly et al 2006</a>].</p></div><div id="ipa.Nomenclature"><h3>Nomenclature</h3><p>Pituitary adenoma predisposition (PAP) syndrome is used to refer to those individuals who have an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. See <a class="figpopup" href="/books/NBK97965/figure/ipa.F1/?report=objectonly" target="object" rid-figpopup="figipaF1" rid-ob="figobipaF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figipaF1" co-legend-rid="figlgndipaF1"><a href="/books/NBK97965/figure/ipa.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figipaF1" rid-ob="figobipaF1"><img class="small-thumb" src="/books/NBK97965/bin/ipa-Image001.gif" src-large="/books/NBK97965/bin/ipa-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndipaF1"><h4 id="ipa.F1"><a href="/books/NBK97965/figure/ipa.F1/?report=objectonly" target="object" rid-ob="figobipaF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Relationship between terms used in the past for familial isolated pituitary adenomas (FIPA) PAP = pituitary adenoma predisposition syndrome</p></div></div></div><div id="ipa.Prevalence"><h3>Prevalence</h3><p>The exact prevalence of <i>AIP</i>-related FIPA is not known. To date, about 50 families and about 50 <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) of <i>AIP</i>-related FIPA have been identified [<a class="bk_pop" href="#ipa.REF.chahal.2010.419">Chahal et al 2010</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</p></div></div><div id="ipa.Genetically_Related_Allelic_Disorder"><h2 id="_ipa_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than <i>AIP</i>-related FIPA are known to be associated with mutation of <i>AIP</i>.</p></div><div id="ipa.Differential_Diagnosis"><h2 id="_ipa_Differential_Diagnosis_">Differential Diagnosis</h2><div id="ipa.Familial_Isolated_Pituitary_Adenoma"><h3>Familial Isolated Pituitary Adenoma (FIPA)</h3><p>FIPA is defined as more than one member of a family with a pituitary adenoma and no other features of a syndrome known to be associated with pituitary adenomas. Except for those with pathogenic variants in <i>AIP</i>, a genetic cause has not yet been determined for the remainder of families with FIPA.</p><p>Families with FIPA of known or unknown cause can have homogeneous pituitary adenoma phenotypes (i.e., pituitary tumors of the same type) or heterogeneous phenotypes (i.e., pituitary tumors of different types).</p><p>Aspects of FIPA that tend to differ between families in which a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified and those in which no germline <i>AIP</i> pathogenic variant has been identified include age of onset, number of persons <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in the family, male to female ratio, and typical adenoma types. Tumor variables may also include size, aggressiveness, and response to treatment [<a class="bk_pop" href="#ipa.REF.chahal.2010.419">Chahal et al 2010</a>] (see <a class="figpopup" href="/books/NBK97965/table/ipa.T.comparison_of_findings_in_persons/?report=objectonly" target="object" rid-figpopup="figipaTcomparisonoffindingsinpersons" rid-ob="figobipaTcomparisonoffindingsinpersons">Table 2</a>).</p><div id="ipa.T.comparison_of_findings_in_persons" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Comparison of Findings in Persons with Pituitary Adenomas by Family History and Presence/Absence of a Germline <i>AIP</i> Pathogenic Variant</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97965/table/ipa.T.comparison_of_findings_in_persons/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ipa.T.comparison_of_findings_in_persons_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" style="text-align:left;vertical-align:middle;"><i>AIP</i>-Related FIPA</th><th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Non-<i>AIP</i> Related</th></tr><tr><th headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">FIPA</th><th headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Simplex somatotropinoma&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinical features</b></td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age of onset&#x000a0;<sup>2</sup></td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18-24 years</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40 years</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">43 years</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Average number <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members&#x000a0;<sup>3</sup></td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-4</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-3</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Male to female ratio&#x000a0;<sup>4</sup></td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2:1</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:1</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:1</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Adenoma features</b></td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Somatotropinomas / somatomammotropinomas</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%-80%</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50%</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Size</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Macroadenomas in vast majority</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Smaller</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Aggressiveness</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">More</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Less</td></tr><tr><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Response to treatment</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Poorer</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Better</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ipa.TF.2.1"><p class="no_margin">Simplex case = a single occurrence in a family</p></div></dd><dt>2. </dt><dd><div id="ipa.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al [2010]</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al [2010]</a></p></div></dd><dt>3. </dt><dd><div id="ipa.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al [2010]</a></p></div></dd><dt>4. </dt><dd><div id="ipa.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#ipa.REF.cazabat.2009.132">Cazabat et al [2009]</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al [2010]</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al [2010]</a></p></div></dd></dl></div></div></div></div><div id="ipa.Other_Causes_of_Pituitary_Tumors"><h3>Other Causes of Pituitary Tumors</h3><p>In children more often than in adults, pituitary tumors may be a manifestation of a genetic condition. In addition to <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenoma, genetic conditions are multiple endocrine neoplasia type 1 and type 4, Carney complex, and McCune-Albright syndrome [<a class="bk_pop" href="#ipa.REF.keil.2008.563">Keil &#x00026; Stratakis 2008</a>].</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/men1/"><b>Multiple endocrine neoplasia type 1</b></a> (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Clinical diagnostic criteria for MEN1 include the presence of two endocrine tumors that are parathyroid, pituitary, or gastro-entero-pancreatic (GEP) tract tumors. The most common endocrine tumor in MEN1 is parathyroid adenoma, with nearly all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals developing hypercalcemia by age 50 years. Pituitary tumors occur in about 40% of persons with MEN1, most often prolactinomas. Mutation of <i>MEN1</i> is causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li><li class="half_rhythm"><div><b>MEN1-like syndrome caused by mutation of <i>CDKN1B</i></b> (encoding cyclin dependent kinase inhibitor 1B), also known as <b>MEN4</b>. The clinical findings are similar to those of MEN1. This syndrome has been reported in five families to date [<a class="bk_pop" href="#ipa.REF.pellegata.2006.15558">Pellegata et al 2006</a>, <a class="bk_pop" href="#ipa.REF.georgitsi.2007b.3321">Georgitsi et al 2007b</a>, <a class="bk_pop" href="#ipa.REF.agarwal.2009.1826">Agarwal et al 2009</a>].</div></li><li class="half_rhythm"><div><a href="/books/n/gene/carney/"><b>Carney complex</b></a> is characterized by skin pigmentary abnormalities, myxomas of the heart and other organs, endocrine tumors or overactivity, and schwannomas. Primary pigmented nodular adrenocortical disease (PPNAD), which causes Cushing syndrome, is the most frequently observed endocrine tumor in Carney complex, occurring in approximately 25% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in one third of affected males within the first decade and in almost all adult males. Up to 75% of individuals with Carney complex have multiple thyroid nodules. Although many affected individuals have somatotroph cell hyperplasia, true adenomas do not develop. Acromegaly has been reported in approximately 10% of adults. About 60% of Carney complex results from mutation of <i>PRKAR1A</i> (encoding protein kinase A1A regulatory subunit); inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/mccune-albright/"><b>McCune-Albright syndrome</b></a> is characterized by polyostotic fibrous dysplasia, caf&#x000e9; au lait patches, and multiple endocrine disorders (e.g., multinodular goiters, multinodular adrenal hyperplasia, precocious puberty, and pituitary adenomas). Increased secretion of growth hormone and prolactin is common in persons with this disorder because of growth hormone-producing adenomas and nodular and diffuse hyperplasia of somatomammotroph cells, respectively [<a class="bk_pop" href="#ipa.REF.horvath.2008.1">Horvath &#x00026; Stratakis 2008</a>]. Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>GNAS</i> (encoding guanine nucleotide-binding protein G(s) subunit alpha <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> short) is causative; no <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases have been reported.</div></li></ul><p><b>Sporadic pituitary tumors.</b> The incidence of symptomatic pituitary tumor in the general population is estimated at 1:1,000 to 1:1,300 [<a class="bk_pop" href="#ipa.REF.daly.2006.4769">Daly et al 2006</a>, <a class="bk_pop" href="#ipa.REF.fernandez.2010.377">Fernandez et al 2010</a>]. Autopsy and radiologic studies suggest that 14%-22% of the population may harbor a pituitary tumor, most of these being asymptomatic [<a class="bk_pop" href="#ipa.REF.ezzat.2004.613">Ezzat et al 2004</a>]. Thus, it is possible for two pituitary tumors, especially prolactinomas, to occur in a family by chance. Instances of phenocopies in families with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been documented [<a class="bk_pop" href="#ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>].</p><p><b>Other.</b> In addition to pituitary adenomas, numerous space-occupying lesions can occur in the pituitary fossa [<a class="bk_pop" href="#ipa.REF.saeger.2007.203">Saeger et al 2007</a>]. The most common space-occupying lesions after pituitary adenomas are craniopharyngiomas, which cause symptoms by compressing the normal pituitary, resulting in hormonal deficiencies and mass effects on the surrounding tissues and brain.</p></div></div><div id="ipa.Management"><h2 id="_ipa_Management_">Management</h2><div id="ipa.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual with <i>AIP</i>-related FIPA, the following evaluations are recommended (for details see <a class="bk_pop" href="#ipa.REF.katznelson.2011.1">Katznelson et al [2011]</a>). Note: The evaluation may have to be individualized depending on the presentation.</p><ul><li class="half_rhythm"><div>Detailed personal history, including findings that may be consistent with the following:</div><ul><li class="half_rhythm"><div>A growth hormone-secreting tumor (stature in relation to the rest of the family, change in facial appearance, change in shoe size, problems with ring sizes, headache, excessive sweating, joint pains, carpal tunnel syndrome)</div></li><li class="half_rhythm"><div>A prolactinoma (menstrual history, galactorrhea, infertility, low libido, impotence)</div></li><li class="half_rhythm"><div>A non-functioning pituitary adenoma and mass effects (headache, lack of other pituitary hormones, visual field problems)</div></li><li class="half_rhythm"><div>Thyrotropinoma (hyperthyroidism with non-suppressed TSH)</div></li><li class="half_rhythm"><div>Corticotropinoma with Cushing disease (truncal obesity, striae, muscle weakness, thin skin, diabetes mellitus, hypertension)</div></li></ul></li><li class="half_rhythm"><div>Review of serial photographs over time to help identify the onset of acromegalic or cushingoid changes if present at the time of diagnosis</div></li><li class="half_rhythm"><div>Measurement of parental heights</div></li><li class="half_rhythm"><div>Clinical examination including measurement of height and documentation of presence or absence of features consistent with the endocrine disorders acromegaly, pituitary gigantism, Cushing disease, thyrotoxicosis</div></li><li class="half_rhythm"><div>Visual field evaluation</div></li><li class="half_rhythm"><div>Basal pituitary function including: spot GH, IGF-1; prolactin; LH, FSH, testosterone/estradiol; TSH, fT4; 9 a.m. cortisol</div></li><li class="half_rhythm"><div>Glucose tolerance test (GTT) in persons with findings of acromegaly to identify abnormal GH dynamics. In addition, about 25% of persons with acromegaly have a diabetic GTT. Assess ACTH reserve if necessary.</div></li><li class="half_rhythm"><div>In adults with acromegaly, colonoscopy at age 40 years with further surveillance at three- to ten-year intervals depending on the presence/absence of adenomas in the initial colonoscopy and IGF-1 levels [<a class="bk_pop" href="#ipa.REF.cairns.2010.666">Cairns et al 2010</a>]</div></li><li class="half_rhythm"><div>Pituitary MRI to detect the size and extent of a tumor, if one is suspected</div></li><li class="half_rhythm"><div>Consultation with specialists in endocrinology</div></li><li class="half_rhythm"><div>Consultation with specialists in clinical genetics to obtain detailed family history (of possible pituitary problems, unusual stature, fertility problems, and/or early death)</div></li></ul></div><div id="ipa.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>While there is experience with treating pituitary adenomas in symptomatic persons with FIPA, there is little experience in the management and treatment of persons identified prospectively through clinical screening due to family history of FIPA and/or presence of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The following recommendations are based on those of <a class="bk_pop" href="#ipa.REF.biller.2008.2454">Biller et al [2008]</a>, <a class="bk_pop" href="#ipa.REF.jaffe.2006.317">Jaffe [2006]</a>, <a class="bk_pop" href="#ipa.REF.katznelson.2011.1">Katznelson et al [2011]</a>, and <a class="bk_pop" href="#ipa.REF.melmed.2011.273">Melmed et al [2011]</a>.</p><p>Pituitary adenomas can be treated by surgery, medical therapy, and/or radiotherapy.</p><p>Adenomas in persons with FIPA, especially those with <i>AIP</i>-related FIPA, are aggressive. Surgery is usually performed, but often does not fully control the tumor. Transsphenoidal surgery has been performed for large adenomas, while microadenomas with normal clinical and biochemistry findings are monitored closely [<a class="bk_pop" href="#ipa.REF.chahal.2011.43">Chahal et al 2011</a>]. Large tumors, especially those recurring after surgery, may require radiotherapy when the tumor invades neighboring anatomic structures (such as the cavernous sinus).</p><p><b>Somatotropinomas,</b> particularly in persons with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, often do not respond to medical therapy with somatostatin analogs. <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al [2010]</a> showed no tumor shrinkage in <i>AIP</i>-related adenomas and significantly lower reductions in GH secretion (40% vs 75%) and IGF-1 secretion (47% and 56%); in these instances growth hormone receptor antagonist therapy could be initiated [<a class="bk_pop" href="#ipa.REF.leontiou.2008.2390">Leontiou et al 2008</a>, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al 2010</a>].</p><p>Radiotherapy (conventional or radiosurgery) is an option for treating growing adenomas, for which repeat surgery is unlikely to control hormone levels.</p><p><b>Prolactinomas</b> are usually treated with dopamine agonist therapy (cabergoline being the drug of choice), which can result in tumor regression or in some cases disappearance of detectable lesions. No data suggest that FIPA-associated prolactinomas would respond less favorably to dopamine agonist therapy than do <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> tumors; however, <a class="bk_pop" href="#ipa.REF.daly.2010.e373">Daly et al [2010]</a> suggested that prolactinomas in <i>AIP-</i>related FIPA appear to be aggressive and difficult to treat. Persons with <i>AIP-</i>related FIPA and a macroprolactinoma (diameter &#x0003e;10 mm) often undergo surgery.</p><p><b>NFPAs</b> are treated with surgery and, if necessary, radiotherapy. They usually do not respond to traditional somatostatin analogs despite the presence of somatostatin receptors and an often good response in vitro. Dopamine agonist therapy has been tried in some cases. Timely diagnosis, prediction of long-term outcome, and treatment of NFPAs remain a challenge for endocrinologists [<a class="bk_pop" href="#ipa.REF.korbonits.2009.123">Korbonits &#x00026; Carlsen 2009</a>].</p><p>Temozolomide has been successfully used for the treatment of a few aggressive pituitary adenomas; however, there is no experience with its use in persons with <i>AIP</i>-related FIPA.</p><p>The increased burden of GH secretion and IGF-1 secretion (defined as the level and duration of increased hormone levels) observed in those with acromegaly is associated with an increased risk for cardiovascular, cerebrovascular, and metabolic complications [<a class="bk_pop" href="#ipa.REF.jayasena.2011.220">Jayasena et al 2011</a>]. Individuals with long-standing acromegaly often have cardiovascular and rheumatologic/orthopedic complications, which need to be treated accordingly.</p></div><div id="ipa.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Tumor size, surgery, and/or radiotherapy can cause hypopituitarism, which needs careful expert follow up.</p><p>Persons on glucocorticoid replacement therapy need to increase their steroid dose when ill or stressed.</p></div><div id="ipa.Surveillance"><h3>Surveillance</h3><p>No guidelines regarding surveillance of persons with <i>AIP</i>-related FIPA have been established. The following recommendations are based on the authors' personal experience with more than 200 persons with symptomatic or asymptomatic <i>AIP</i>-related FIPA.</p><p><b>Persons with <i>AIP</i>-related FIPA who have had a pituitary adenoma.</b> The following are recommended to monitor for recurrence of the previous adenoma and development of new adenomas.</p><ul><li class="half_rhythm"><div>Yearly clinical assessment and basal pituitary function (IGF-1, spot GH, prolactin, LH/FSH, estradiol/testosterone, TSH, fT4, morning cortisol) and if necessary dynamic testing (e.g., glucose tolerance test, insulin tolerance test) to evaluate for hormone excess or deficiency</div></li><li class="half_rhythm"><div>Repeat pituitary MRI. Note: Frequency depends on clinical status, previous extent of the tumor, and treatment modality.</div></li></ul><p><b>Persons with acromegaly.</b> Follow established guidelines regarding clinical monitoring for related complications including diabetes mellitus, hypertension, osteoarthritis, and colon cancer.</p><p><b>Persons with hypogonadism.</b> Follow established guidelines. Because long-standing untreated hypogonadism may result in the early onset of osteoporosis, bone density needs to be assessed at baseline and if necessary monitored with DEXA scanning.</p><p><b>Persons with an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and no history of pituitary adenomas.</b> Recommendations follow. Note, however, that long-term experience with asymptomatic <i>AIP</i> heterozygotes is limited; more data are needed to develop appropriate future guidelines.</p><p>In a family in which an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified, relatives who have the family-specific <i>AIP</i> pathogenic variant or who have not been tested:</p><p><b>Adults</b></p><ul><li class="half_rhythm"><div>Baseline<i>.</i> Clinical assessment, pituitary function tests (IGF-1, prolactin, estradiol/testosterone, LH, FSH, and fT4), and pituitary MRI</div></li><li class="half_rhythm"><div>Thereafter</div><ul><li class="half_rhythm"><div>Perform annual clinical assessment and pituitary function tests.</div></li><li class="half_rhythm"><div>Consider repeating a pituitary MRI every five years if clinical findings and pituitary function tests remain normal.</div></li><li class="half_rhythm"><div>Consider discontinuing monitoring about age 50 years, after which the likelihood of developing new pituitary adenomas is low.</div></li></ul></li></ul><p><b>Children</b></p><ul><li class="half_rhythm"><div>Yearly beginning at age four years</div><ul><li class="half_rhythm"><div>Measure height and weight with calculation of height velocity. Document pubertal development, Tanner stages.</div></li><li class="half_rhythm"><div>Perform pituitary function tests (as for adults).</div></li></ul></li><li class="half_rhythm"><div>Perform baseline pituitary MRI at about age ten years.</div></li><li class="half_rhythm"><div>Consider repeating the pituitary MRI every five years if clinical and pituitary function tests remain normal.</div></li></ul></div><div id="ipa.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to at-risk relatives if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member so that morbidity and mortality can be reduced by early diagnosis and treatment.</p><p>See <a href="#ipa.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ipa.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy may increase the size of a growth hormone-secreting adenoma or a prolactin-secreting adenoma (especially macroadenomas); thus, a pregnant woman with pituitary macroadenoma is at risk of developing visual field defects. In each trimester it is appropriate to inquire about headaches and perform visual field testing.</p></div><div id="ipa.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A study that is actively ascertaining individuals with FIPA or childhood-onset pituitary adenoma is listed in <a href="http://www.clinicaltrials.gov/ct2/show/NCT00461188?term=NCT00461188&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>.</p><p>Growth hormone receptor antagonists block the action of endogenous growth hormone, thereby controlling disease manifestations such as headaches, soft tissue enlargement, diabetes mellitus, hypertension, and high IGF-1 levels. A growth hormone receptor antagonist has been used successfully in persons with <i>AIP</i>-related FIPA and acromegaly and pituitary gigantism [<a class="bk_pop" href="#ipa.REF.goldenberg.2008.2953">Goldenberg et al 2008</a>; Author, personal observation]. Although growth hormone receptor antagonists are currently not licensed for pediatric use, several case reports have shown their effectiveness, especially when IGF-1 levels need to be reduced immediately to prevent abnormally rapid growth [<a class="bk_pop" href="#ipa.REF.higham.2010.280">Higham et al 2010</a>].</p><p>Search <a href="http://www.ClinicalTrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ipa.Genetic_Counseling"><h2 id="_ipa_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ipa.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>AIP</i>-related <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenoma (<i>AIP</i>-related FIPA) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div><div id="ipa.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Almost all individuals reported to date with <i>AIP</i>-related FIPA have a parent who is also <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ipa.REF.chahal.2010.419">Chahal et al 2010</a>, <a class="bk_pop" href="#ipa.REF.stratakis.2010.457">Stratakis et al 2010</a>]. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, the parent may not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">If the disease-predisposing variant found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the proband, assuming paternity is as stated. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div class="half_rhythm">As not all <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> <i>AIP</i>-related FIPA cases (i.e., a single occurrence in a family) have been evaluated sufficiently to determine if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, the proportion of <i>AIP</i>-related FIPA resulting from a <i>de novo</i>
<i>AIP</i> pathogenic variant is unknown. However, this is likely to be low: to date, only one case of proven <i>de novo</i> mutation has been reported in an individual with a childhood-onset corticotroph adenoma [<a class="bk_pop" href="#ipa.REF.stratakis.2010.457">Stratakis et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>AIP</i>-related FIPA include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband.</div><div class="half_rhythm">Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but has escaped previous diagnosis because of a milder phenotypic presentation or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the pathogenic variant is 50%.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. No instances of germline mosaicism have been reported to date.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a 50% chance of inheriting the pathogenic variant.</p><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents.</div></li><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk for <i>AIP</i>-related FIPA.</div></li></ul></div><div id="ipa.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ipa.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant, it is possible that mutation occurred <i>de novo</i> in the proband. However, possible non-medical explanations include <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction), or undisclosed adoption.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ipa.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for FIPA are possible.</p><p>As <i>AIP</i>-related FIPA demonstrates reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, the finding of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AIP</i> prenatally does not allow accurate prediction of a tumor, the adenoma type, age of onset, prognosis, or availability of and/or outcome of treatment.</p><p>Requests for prenatal testing for conditions which (like <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenomas) do not affect intellect and have some treatment available are rare. In addition, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, though not yet adequately studied, is thought to be reduced in most families. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While decisions regarding prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ipa.Resources"><h2 id="_ipa_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>FIPA Patients</b></div><div><i>Familial Isolated Pituitary Adenoma</i></div><div><b>Email:</b> info@fipapatients.org</div><div><a href="http://www.fipapatients.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fipapatients.org</a></div></li><li class="half_rhythm"><div><b>AMEND Research Registry </b></div><div>The Warehouse</div><div>Draper Street</div><div>Tunbridge Wells Kent TN4 0PG</div><div>United Kingdom</div><div><b>Phone:</b> +44 1892 516076</div><div><b>Email:</b> jo.grey@amend.org.uk</div><div><a href="https://www.amend.org.uk/patients/research-opportunities/uk-national-men1-and-pnet-research-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UK National MEN1 &#x00026; PNET Research Registry</a></div></li><li class="half_rhythm"><div><b>FIPA Consortium Registry</b></div><div><i>Patients with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pituitary adenoma or childhood onset pituitary disease and their families are encouraged to contact the registry.</i></div><div><b>Email:</b> info@fipapatients.org</div><div><a href="http://www.fipapatients.org/contact" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fipapatients.org/contact</a></div></li></ul></div><div id="ipa.Molecular_Genetics"><h2 id="_ipa_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ipa.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>AIP-Related Familial Isolated Pituitary Adenomas : Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97965/table/ipa.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ipa.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ipa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ipa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ipa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ipa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ipa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ipa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ipa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/9049" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AIP</i></a></td><td headers="hd_b_ipa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=9049" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ipa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O00170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AH receptor-interacting protein</a></td><td headers="hd_b_ipa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.fipapatients.org/aip" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AIP Gene Mutations</a><br /><a href="http://databases.lovd.nl/shared/genes/AIP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AIP database</a></td><td headers="hd_b_ipa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AIP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AIP</a></td><td headers="hd_b_ipa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AIP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AIP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ipa.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ipa.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for AIP-Related Familial Isolated Pituitary Adenomas (<a href="/omim/102200,219090,600634,605555" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97965/table/ipa.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ipa.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/102200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">102200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PITUITARY ADENOMA 1, MULTIPLE TYPES; PITA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/219090" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">219090</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PITUITARY ADENOMA 4, ACTH-SECRETING; PITA4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600634" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600634</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PITUITARY ADENOMA, PROLACTIN-SECRETING</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605555" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605555</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; AIP</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>AIP</i> comprises six exons encoding a 330-amino acid protein. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK97965/#ipa.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>.</b> The variant c.47G&#x0003e;A (p.Arg16His), identified in a few <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of acromegaly (including some childhood-onset cases), was also found in three of 360 controls [<a class="bk_pop" href="#ipa.REF.cazabat.2007.1">Cazabat et al 2007</a>, <a class="bk_pop" href="#ipa.REF.daly.2007.1891">Daly et al 2007</a>, <a class="bk_pop" href="#ipa.REF.georgitsi.2007a.4101">Georgitsi et al 2007a</a>, <a class="bk_pop" href="#ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</a>]. It was identified in 0.3% of European Americans and 0.08% of African Americans in the general population. An in vitro functional study of loss of binding to one of the partners of AIP (phosphodiesterase [PDE] subtype 4A5) did not show a significant functional change [<a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>]. Furthermore, in a family with FIPA the c.47G&#x0003e;A (p.Arg16His) variant did not segregate with pituitary adenomas [<a class="bk_pop" href="#ipa.REF.guaraldi.2011.55">Guaraldi &#x00026; Salvatori 2011</a>].</p><p>The variant c.145G&#x0003e;A (p.Val49Met), reported in one <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case of gigantism, did not show <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> [<a class="bk_pop" href="#ipa.REF.iwata.2007.499">Iwata et al 2007</a>] or loss of binding to one of the partners of AIP (phosphodiesterase [PDE] subtype 4A5) [<a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>]. Of note, loss of in vitro PDE binding does not necesserily correspond to clinically important loss of function; however, few functional tests for AIP are currently available and none has proven clinical relevance.</p><p>The variant c.896C&#x0003e;T (p.Ala299Val) was reported in a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case of acromegaly [<a class="bk_pop" href="#ipa.REF.georgitsi.2007a.4101">Georgitsi et al 2007a</a>] and in <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> asymptomatic persons whose other <i>AIP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has the p.Arg304Ter pathogenic truncating variant. The c.896C&#x0003e;T variant is unlikely to reduce the function of the AIP protein significantly, as <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> inactivation of <i>AIP</i> in humans may be an embryonic lethal event, as was demonstrated in mice with a complete <i>Aip</i> knockout.</p><p><b>Pathogenic variants.</b> About 50 different <i>AIP</i> pathogenic variants have been reported, including <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, intragenic deletions and insertions, and deletions of one or more exons. See <a class="figpopup" href="/books/NBK97965/table/ipa.T.selected_aip_variants/?report=objectonly" target="object" rid-figpopup="figipaTselectedaipvariants" rid-ob="figobipaTselectedaipvariants">Table 3</a>, <a href="/books/NBK97965/bin/ipa-Table4.pdf">Table 4</a> (pdf).</p><p>Most pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affect the TPR (tetratricopeptide repeat) (see <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>) domains or the C-terminal alpha-helix. This supports the earlier evidence that the TPR domains and the last five C-terminal amino acids are important for the activity of AIP [<a class="bk_pop" href="#ipa.REF.petrulis.2002.25">Petrulis &#x00026; Perdew 2002</a>].</p><p>Recurrent <i>AIP</i> pathogenic variants include:</p><ul><li class="half_rhythm"><div>p.Arg304Ter or p.Arg304Gln in several independent families and several <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases. Out of the several individuals with the p.Arg304Ter variant, two independent clusters (in Ireland and Italy) were shown result from a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> [<a class="bk_pop" href="#ipa.REF.occhi.2010.800">Occhi et al 2010</a>, <a class="bk_pop" href="#ipa.REF.chahal.2011.43">Chahal et al 2011</a>].</div></li><li class="half_rhythm"><div>p.Arg81Ter in two families</div></li><li class="half_rhythm"><div>p.Arg271Trp in two families and a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case of pituitary gigantism</div></li><li class="half_rhythm"><div>c.807C&#x0003e;T in one family and three <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases</div></li><li class="half_rhythm"><div>c.805_825dup (p.Phe269_His275dup) segmental <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>, identified in five apparently independent families (Note: This duplication is detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.)</div></li><li class="half_rhythm"><div>p.Gln14Ter in a few families and several <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases from Finland, suggesting the presence of a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a></div></li></ul><div id="ipa.T.selected_aip_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>AIP</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97965/table/ipa.T.selected_aip_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ipa.T.selected_aip_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ipa.T.selected_aip_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant<br />Classification</th><th id="hd_h_ipa.T.selected_aip_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ipa.T.selected_aip_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ipa.T.selected_aip_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Uncertain</b><br /><b>significance</b></td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.47G&#x0003e;A</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg16His</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_4" rowspan="11" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_003977.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003977<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_003968.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003968<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.145G&#x0003e;A</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val49Met</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.896C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala299Val</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.40C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln14Ter</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.241C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg81Ter</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.807C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.=&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.721A&#x0003e;G</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys241Glu</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.805_825dup</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe269_His275dup</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.811C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg271Trp</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.911G&#x0003e;A</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg304Gln</td></tr><tr><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.910C&#x0003e;T</td><td headers="hd_h_ipa.T.selected_aip_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg304Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ipa.TF.3.1"><p class="no_margin">p.= designates that protein has not been analyzed, but no change is expected.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>AIP</i> is a tumor suppressor gene [<a class="bk_pop" href="#ipa.REF.leontiou.2008.2390">Leontiou et al 2008</a>]. Its protein product, AIP, previously known as hepatitis B virus (HBV) X-associated protein (XAP2) or aryl hydrocarbon receptor (AhR)-associated protein (ARA9), is a 330-amino acid 37-kd protein [<a class="bk_pop" href="#ipa.REF.kuzhandaivelu.1996.4741">Kuzhandaivelu et al 1996</a>, <a class="bk_pop" href="#ipa.REF.carver.1997.11452">Carver &#x00026; Bradfield 1997</a>]. The C-terminal end of the protein has three tetratricopeptide repeats (TPRs) and a final alpha-helix. The three TPR domains are degenerate sequences of 34 amino acids comprising two antiparallel helices that play a crucial role in mediating the protein-protein interactions of AIP [<a class="bk_pop" href="#ipa.REF.kazlauskas.2002.11795">Kazlauskas et al 2002</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The majority (70%) of <i>AIP</i> variants result in, or predict, a truncated protein. Many of the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affect structurally important conserved amino acids of the TPR structure [<a class="bk_pop" href="#ipa.REF.vargiolu.2009.2571">Vargiolu et al 2009</a>, <a class="bk_pop" href="#ipa.REF.igreja.2010.950">Igreja et al 2010</a>, <a class="bk_pop" href="#ipa.REF.cai.2011.e25201">Cai et al 2011</a>]. Clinical data and functional studies both indicate a tumor suppressor role for AIP.</p></div><div id="ipa.References"><h2 id="_ipa_References_">References</h2><div id="ipa.Published_Guidelines__Consensus_Stat"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.katznelson">Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. [<a href="/pubmed/21846616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21846616</span></a>]</div></li></ul></div><div id="ipa.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.agarwal.2009.1826">Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:1826–34.</span> [<a href="/pmc/articles/PMC2684477/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2684477</span></a>] [<a href="/pubmed/19141585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19141585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.biller.2008.2454">Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008;<span class="ref-vol">93</span>:2454–62.</span> [<a href="/pmc/articles/PMC3214276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3214276</span></a>] [<a href="/pubmed/18413427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18413427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cai.2011.e25201">Cai W, Kramarova TV, Berg P, Korbonits M, Pongratz I. The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor &#x003b1;. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e25201.</span> [<a href="/pmc/articles/PMC3184960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3184960</span></a>] [<a href="/pubmed/21984905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21984905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cain.2010.681">Cain JW, Miljic D, Popovic V, Korbonits M. Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. <span><span class="ref-journal">Expert Rev Endocrinol Metab. </span>2010;<span class="ref-vol">5</span>:681–95.</span> [<a href="/pubmed/30764022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30764022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cairns.2010.666">Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR, et al.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). <span><span class="ref-journal">Gut. </span>2010;<span class="ref-vol">59</span>:666–89.</span> [<a href="/pubmed/20427401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20427401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.carver.1997.11452">Carver LA, Bradfield CA. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:11452–6.</span> [<a href="/pubmed/9111057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9111057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cazabat.2011.1973">Cazabat L, Bouligand J, Chanson P. AIP mutation in pituitary adenomas. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1973–4.</span> [<a href="/pubmed/21591954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21591954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cazabat.2009.132">Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">71</span>:132–41.</span> [<a href="/pubmed/19188737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19188737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.cazabat.2007.1">Cazabat L, Lib&#x000e8; R, Perlemoine K, Ren&#x000e9;-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. <span><span class="ref-journal">Eur J Endocrinol. </span>2007;<span class="ref-vol">157</span>:1–8.</span> [<a href="/pubmed/17609395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17609395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.chahal.2010.419">Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). <span><span class="ref-journal">Trends Endocrinol Metab. </span>2010;<span class="ref-vol">21</span>:419–27.</span> [<a href="/pubmed/20570174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20570174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.chahal.2011.43">Chahal HS, Stals K, Unterl&#x000e4;nder M, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ, Howlett TA, Levy MJ, Orme SM, Akker SA, Abel RL, Grossman AB, Burger J, Ellard S, Korbonits M. AIP mutation in pituitary adenomas in the 18th century and today. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:43–50.</span> [<a href="/pubmed/21208107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21208107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.daly.2006.4769">Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:4769–75.</span> [<a href="/pubmed/16968795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16968795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.daly.2010.e373">Daly AF, Tichomirowa MA, Petrossians P, Heli&#x000f6;vaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Monta&#x000f1;ana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabat&#x000e9; MI, Villa C, Popelier M, Salvatori R, Jennings J, Long&#x000e1;s AF, Labarta Aizp&#x000fa;n JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:E373–83.</span> [<a href="/pubmed/20685857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20685857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.daly.2007.1891">Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabat&#x000e9; MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, W&#x000e9;meau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Monta&#x000f1;ana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:1891–6.</span> [<a href="/pubmed/17244780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17244780</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.de_groot.2010">De Groot LJ, Jameson JL. <em>Endocrinology</em>. Philadelphia, PA: Elsevier; 2010.</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.ezzat.2004.613">Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. <span><span class="ref-journal">Cancer. </span>2004;<span class="ref-vol">101</span>:613–9.</span> [<a href="/pubmed/15274075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15274075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.fernandez.2010.377">Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2010;<span class="ref-vol">72</span>:377–82.</span> [<a href="/pubmed/19650784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19650784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.georgitsi.2008a.621">Georgitsi M, De Menis E, Cannav&#x000f2; S, M&#x000e4;kinen MJ, Tuppurainen K, Pauletto P, Curt&#x000f2; L, Weil RJ, Paschke R, Zielinski G, Wasik A, Lubinski J, Vahteristo P, Karhu A, Aaltonen LA. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2008a;<span class="ref-vol">69</span>:621–7.</span> [<a href="/pubmed/18410548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18410548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.georgitsi.2008b.4146">Georgitsi M, Heli&#x000f6;vaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O, Salmela P, Sane T, De Menis E, Cannav&#x000f2; S, G&#x000fc;ndogdu S, Lucassen A, Izatt L, Aylwin S, Bano G, Hodgson S, Koch CA, Karhu A, Aaltonen LA. Large genomic deletions in AIP in pituitary adenoma predisposition. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008b;<span class="ref-vol">93</span>:4146–51.</span> [<a href="/pubmed/18628514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18628514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.georgitsi.2007a.4101">Georgitsi M, Raitila A, Karhu A, Tuppurainen K, M&#x000e4;kinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O, Lubinski J, Launonen V, Vahteristo P, Aaltonen LA. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007a;<span class="ref-vol">104</span>:4101–5.</span> [<a href="/pmc/articles/PMC1820715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1820715</span></a>] [<a href="/pubmed/17360484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17360484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.georgitsi.2007b.3321">Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, M&#x000e4;kinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, G&#x000fc;ndogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007b;<span class="ref-vol">92</span>:3321–5.</span> [<a href="/pubmed/17519308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17519308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.goldenberg.2008.2953">Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008;<span class="ref-vol">93</span>:2953–6.</span> [<a href="/pmc/articles/PMC2515082/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2515082</span></a>] [<a href="/pubmed/18492755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18492755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.guaraldi.2011.55">Guaraldi F, Salvatori R. Familial isolated pituitary adenomas: from genetics to therapy. <span><span class="ref-journal">Clin Transl Sci. </span>2011;<span class="ref-vol">4</span>:55–62.</span> [<a href="/pmc/articles/PMC5439841/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5439841</span></a>] [<a href="/pubmed/21348957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21348957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.higham.2010.280">Higham CE, Emy P, Ferone D, Finke R, Laurberg P, Main K, Maffei P, Martini C, Minuto F, Rainegard I, Salzgeber K, Vogel C, Koltowska-Haggstrom M, Trainer PJ. Treatment experience in 11 patients with gigantism. <span><span class="ref-journal">Endocrine Abstracts. </span>2010;<span class="ref-vol">21</span>:280.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.horvath.2008.1">Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. <span><span class="ref-journal">Rev Endocr Metab Disord. </span>2008;<span class="ref-vol">9</span>:1–11.</span> [<a href="/pubmed/18200440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18200440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.igreja.2010.950">Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K, Stals K, Khoo B, Kumar AV, Ellard S, Grossman AB, Korbonits M, et al.  Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:950–60.</span> [<a href="/pmc/articles/PMC3065644/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3065644</span></a>] [<a href="/pubmed/20506337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20506337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.iwata.2007.499">Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2007;<span class="ref-vol">66</span>:499–502.</span> [<a href="/pubmed/17371465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17371465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.jaffe.2006.317">Jaffe CA. Clinically non-functioning pituitary adenoma. <span><span class="ref-journal">Pituitary. </span>2006;<span class="ref-vol">9</span>:317–21.</span> [<a href="/pubmed/17082898" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17082898</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.jayasena.2011.220">Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2011;<span class="ref-vol">75</span>:220–5.</span> [<a href="/pubmed/21521288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21521288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.katznelson.2011.1">Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. <span><span class="ref-journal">Endocr Pract. </span>2011;<span class="ref-vol">17</span> Suppl 4:1–44.</span> [<a href="/pubmed/21846616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21846616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.kazlauskas.2002.11795">Kazlauskas A, Poellinger L, Pongratz I. Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:11795–801.</span> [<a href="/pubmed/11805120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11805120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.keil.2008.563">Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. <span><span class="ref-journal">Expert Rev Neurother. </span>2008;<span class="ref-vol">8</span>:563–74.</span> [<a href="/pmc/articles/PMC2743125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2743125</span></a>] [<a href="/pubmed/18416659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18416659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.khoo.2009.1057">Khoo SK, Pendek R, Nickolov R, Luccio-Camelo DC, Newton TL, Massie A, Petillo D, Menon J, Cameron D, Teh BT, Chan SP. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. <span><span class="ref-journal">Endocr Relat Cancer. </span>2009;<span class="ref-vol">16</span>:1057–63.</span> [<a href="/pubmed/19443539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19443539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.korbonits.2009.123">Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">71</span> Suppl 2:123–30.</span> [<a href="/pubmed/19407508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19407508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.korbonits.2012.351">Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas - who should be tested for AIP mutations? <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2012;<span class="ref-vol">77</span>:351–6.</span> [<a href="/pubmed/22612670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22612670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.kuzhandaivelu.1996.4741">Kuzhandaivelu N, Cong YS, Inouye C, Yang WM, Seto E. XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation. <span><span class="ref-journal">Nucleic Acids Res. </span>1996;<span class="ref-vol">24</span>:4741–50.</span> [<a href="/pmc/articles/PMC146319/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC146319</span></a>] [<a href="/pubmed/8972861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8972861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.leontiou.2008.2390">Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008;<span class="ref-vol">93</span>:2390–401.</span> [<a href="/pubmed/18381572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18381572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.melmed.2011.273">Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:273–88.</span> [<a href="/pubmed/21296991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21296991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.naves.2007.383">Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalh&#x000e3;es AV, Azevedo MF, Giacomini LA, Nascimento PP, Nunes RO, Rosa JW, Jaffrain-Rea ML, Bours V, Beckers A. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. <span><span class="ref-journal">Eur J Endocrinol. </span>2007;<span class="ref-vol">157</span>:383–91.</span> [<a href="/pubmed/17893251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17893251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.occhi.2010.800">Occhi G, Jaffrain-Rea ML, Trivellin G, Albiger N, Ceccato F, De Menis E, Angelini M, Ferasin S, Beckers A, Mantero F, Scaroni C. The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: mutational hot-spot or founder effect? <span><span class="ref-journal">J Endocrinol Invest. </span>2010;<span class="ref-vol">33</span>:800–5.</span> [<a href="/pubmed/20354355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20354355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.pellegata.2006.15558">Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, H&#x000f6;fler H, Fend F, Graw J, Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2006;<span class="ref-vol">103</span>:15558–63.</span> [<a href="/pmc/articles/PMC1622862/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1622862</span></a>] [<a href="/pubmed/17030811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17030811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.petrulis.2002.25">Petrulis JR, Perdew GH. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. <span><span class="ref-journal">Chem Biol Interact. </span>2002;<span class="ref-vol">141</span>:25–40.</span> [<a href="/pubmed/12213383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12213383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.saeger.2007.203">Saeger W, L&#x000fc;decke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. <span><span class="ref-journal">Eur J Endocrinol. </span>2007;<span class="ref-vol">156</span>:203–16.</span> [<a href="/pubmed/17287410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17287410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.stratakis.2010.457">Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M, Verma S, Daly AF, Raygada M, Keil MF, Papademetriou J, Drori-Herishanu L, Horvath A, Tsang KM, Nesterova M, Franklin S, Vanbellinghen JF, Bours V, Salvatori R, Beckers A. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. <span><span class="ref-journal">Clin Genet. </span>2010;<span class="ref-vol">78</span>:457–63.</span> [<a href="/pmc/articles/PMC3050035/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3050035</span></a>] [<a href="/pubmed/20507346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20507346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.tichomirowa.2011.509">Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Sch&#x000fc;rmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Monta&#x000f1;ana CF, Hana V, Halaby G, Delemer B, Aizp&#x000fa;n JI, Sonnet E, Long&#x000e1;s AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. <span><span class="ref-journal">Eur J Endocrinol. </span>2011;<span class="ref-vol">165</span>:509–15.</span> [<a href="/pubmed/21753072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21753072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.vargiolu.2009.2571">Vargiolu M, Fusco D, Kurelac I, Dirnberger D, Baumeister R, Morra I, Melcarne A, Rimondini R, Romeo G, Bonora E. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:2571–8.</span> [<a href="/pubmed/19366855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19366855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.vierimaa.2006.1228">Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, G&#x000fc;ndogdu S, De Menis E, M&#x000e4;kinen MJ, Launonen V, Karhu A, Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. <span><span class="ref-journal">Science. </span>2006;<span class="ref-vol">312</span>:1228–30.</span> [<a href="/pubmed/16728643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16728643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ipa.REF.villa.2011.347">Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, Bouligand J, Junier MP, Di Rocco F, Sainte-Rose C, Beckers A, Roux FX, Daly AF, Chiovato L. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. <span><span class="ref-journal">Endocr Relat Cancer. </span>2011;<span class="ref-vol">18</span>:347–56.</span> [<a href="/pubmed/21450940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21450940</span></a>]</div></li></ul></div></div><div id="ipa.Chapter_Notes"><h2 id="_ipa_Chapter_Notes_">Chapter Notes</h2><div id="ipa.Author_Notes"><h3>Author Notes</h3><p><b>Website:</b>
<a href="http://www.fipapatients.org/about/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fipapatients.org</a></p><p>The FIPA Patients website, established by Dr. Korbonits in collaboration with the <a href="http://www.fipapatients.org/fipaconsortium/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FIPA Consortium</a>, is an information resource for patients and families with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pituitary adenoma. It also provides general information for medical professionals on <a href="http://www.fipapatients.org/research/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">research</a> in the field of FIPA, including <a href="http://www.fipapatients.org/references/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">links to relevant publications</a>.</p><p>The authors welcome comments and inquiries: <a href="mailto:dev@null" data-email="gro.stneitapapif@ofni:otliam" class="oemail">gro.stneitapapif@ofni:otliam</a>.</p></div><div id="ipa.Acknowledgments"><h3>Acknowledgments</h3><p>We are grateful to referring colleagues and patients for providing information on this disease. We are grateful for the expert help of Giampaolo Trivellin in the compilation of Table 4.</p></div><div id="ipa.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 June 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>3 February 2011 (mk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK97965</span><span class="label">PMID: <a href="/pubmed/22720333" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">22720333</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/adnp-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alk-nbs/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK97965&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK97965/?report=reader">PubReader</a></li><li><a href="/books/NBK97965/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK97965" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK97965" style="display:none" title="Cite this Page"><div class="bk_tt">Korbonits M, Kumar AV. AIP-Related Familial Isolated Pituitary Adenomas. 2012 Jun 21. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK97965/pdf/Bookshelf_NBK97965.pdf">PDF version of this page</a> (511K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ipa.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ipa.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ipa.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ipa.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ipa.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ipa.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ipa.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ipa.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ipa.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ipa.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ipa.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9049[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AIP</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9101[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">USP8</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK97965+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2925028" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2925028" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2925028" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2925028" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23371967" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.</a><span class="source">[Endocr Rev. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Beckers A, Aaltonen LA, Daly AF, Karhu A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Endocr Rev. 2013 Apr; 34(2):239-77. Epub 2013 Jan 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27838609" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.</a><span class="source">[Hormones (Athens). 2016]</span><div class="brieflinkpop offscreen_noflow">A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cansu GB, Taşkıran B, Trivellin G, Faucz FR, Stratakis CA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hormones (Athens). 2016 Jul; 15(3):441-444. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17244780" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.</a><span class="source">[J Clin Endocrinol Metab. 2007]</span><div class="brieflinkpop offscreen_noflow">Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Endocrinol Metab. 2007 May; 92(5):1891-6. Epub 2007 Jan 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17893250" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The clinical, pathological, and genetic features of familial isolated pituitary adenomas.</a><span class="source">[Eur J Endocrinol. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The clinical, pathological, and genetic features of familial isolated pituitary adenomas.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Beckers A, Daly AF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Endocrinol. 2007 Oct; 157(4):371-82. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301710" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple Endocrine Neoplasia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple Endocrine Neoplasia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Giusti F, Marini F, Brandi ML. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=22720333" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=22720333" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0415ab75f66d18aa4f9245">AIP-Related Familial Isolated Pituitary Adenomas - GeneReviews®</a><div class="ralinkpop offscreen_noflow">AIP-Related Familial Isolated Pituitary Adenomas - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:06:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CDEE6E04027E100000000080D02DB&amp;ncbi_session=CE8CDEE6E0415AA1_2061SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK97965%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK97965&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK97965/&amp;ncbi_pagename=AIP-Related Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CDEE6E0415AA1_2061SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>